Syquant Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-4,500
Closed -$339K – 44
2022
Q2
$339K Buy
+4,500
New +$200K 0.38% 21
2021
Q1
– Sell
-5,000
Closed -$609K – 85
2020
Q4
$609K Buy
+5,000
New +$548K 0.16% 66

Syquant Capital's TPTX Position: Q3 2022 in Review

Syquant Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 4,500 shares — an estimated $339K sold.

Syquant Capital first reported a position in TPTX in Q4 2020 and held it in 2 quarters. The position peaked at $609K in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Syquant Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Syquant Capital sold 4,500 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $339K.
  • Syquant Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Syquant Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $609K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Syquant Capital's 13F filing for Q3 2022, filed 11 Oct 2022.